Medigen Vaccine Biologics (6547) - Total Assets
Based on the latest financial reports, Medigen Vaccine Biologics (6547) holds total assets worth NT$3.93 Billion TWD (≈ $123.94 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore debt repayment capacity of Medigen Vaccine Biologics to assess how comfortably operating cash covers total debt obligations.
Medigen Vaccine Biologics - Total Assets Trend (2012–2025)
This chart illustrates how Medigen Vaccine Biologics's total assets have evolved over time, based on quarterly financial data. See 6547 book value for net asset value and shareholders' equity analysis.
Medigen Vaccine Biologics - Asset Composition Analysis
Current Asset Composition (December 2025)
Medigen Vaccine Biologics's total assets of NT$3.93 Billion consist of 60.1% current assets and 39.9% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 15.1% |
| Accounts Receivable | NT$130.02 Million | 3.3% |
| Inventory | NT$393.75 Million | 10.0% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$21.14 Million | 0.5% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Medigen Vaccine Biologics's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Medigen Vaccine Biologics market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Medigen Vaccine Biologics's current assets represent 60.1% of total assets in 2025, an increase from 30.0% in 2012.
- Cash Position: Cash and equivalents constituted 15.1% of total assets in 2025, down from 26.5% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 65.0% in 2012.
- Asset Diversification: The largest asset category is inventory at 10.0% of total assets.
Medigen Vaccine Biologics Competitors by Total Assets
Key competitors of Medigen Vaccine Biologics based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
Pharvaris BV
NASDAQ:PHVS
|
USA | $338.90 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.38 Billion |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
|
NANOBIOTIX S.A. SP.ADR
F:5NRA
|
Germany | €67.76 Million |
Medigen Vaccine Biologics - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 12.77 | 11.94 | 7.58 |
| Quick Ratio | 10.64 | 9.83 | 7.22 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$2.18 Billion | NT$2.34 Billion | NT$1.69 Billion |
Medigen Vaccine Biologics - Advanced Valuation Insights
This section examines the relationship between Medigen Vaccine Biologics's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.46 |
| Latest Market Cap to Assets Ratio | 0.14 |
| Asset Growth Rate (YoY) | -9.9% |
| Total Assets | NT$3.93 Billion |
| Market Capitalization | $534.44 Million USD |
Valuation Analysis
Below Book Valuation: The market values Medigen Vaccine Biologics's assets below their book value (0.14x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Medigen Vaccine Biologics's assets decreased by 9.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Medigen Vaccine Biologics (2012–2025)
The table below shows the annual total assets of Medigen Vaccine Biologics from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | NT$3.93 Billion ≈ $123.94 Million |
-9.85% |
| 2024-12-31 | NT$4.36 Billion ≈ $137.49 Million |
-28.37% |
| 2023-12-31 | NT$6.09 Billion ≈ $191.95 Million |
-17.08% |
| 2022-12-31 | NT$7.35 Billion ≈ $231.49 Million |
+38.66% |
| 2021-12-31 | NT$5.30 Billion ≈ $166.95 Million |
+51.80% |
| 2020-12-31 | NT$3.49 Billion ≈ $109.98 Million |
+53.30% |
| 2019-12-31 | NT$2.28 Billion ≈ $71.74 Million |
+4.30% |
| 2018-12-31 | NT$2.18 Billion ≈ $68.78 Million |
+2.18% |
| 2017-12-31 | NT$2.14 Billion ≈ $67.31 Million |
+17.56% |
| 2016-12-31 | NT$1.82 Billion ≈ $57.26 Million |
+9.91% |
| 2015-12-31 | NT$1.65 Billion ≈ $52.09 Million |
+36.13% |
| 2014-12-31 | NT$1.21 Billion ≈ $38.27 Million |
+154.43% |
| 2013-12-31 | NT$477.40 Million ≈ $15.04 Million |
+217.95% |
| 2012-12-31 | NT$150.15 Million ≈ $4.73 Million |
-- |
About Medigen Vaccine Biologics
Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for th… Read more